Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04898634 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
A Phase 1 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 216
- Enrollment target
- 17
- Study locations
NCT04898634: Active Phase 1 study of Prostatic Neoplasms, sponsored by Janssen Research & Development.
NCT04898634 is a Phase 1 study of Prostatic Neoplasms that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 216 participants, below the 511-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (58% lower). The trial reports 17 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04898634, a Phase 1 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 216 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Primary Outcome
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
Conditions Studied
Interventions
- DRUG JNJ-78278343
Study Locations (17)
Other
- Peking University Third Hospital - Beijing
- Chongqing University Cancer Hospital - Chongqing
- Sun Yat Sen University Cancer Center - Guangzhou
- First Affiliated Hospital Of Wenzhou Medical College - Wenzhou
- Centre Leon Berard - Lyon
- APHM Hopital Timone - Marseille
- Institut Gustave Roussy - Villejuif
- National Cancer Center Hospital East - Kashiwa
- Yokohama City University Medical Center - Yokohama
- Antoni van Leeuwenhoek - Amsterdam
- Erasmus MC - Rotterdam
- Hosp Univ Fund Jimenez Diaz - Madrid
- Hosp Univ Hm Sanchinarro - Madrid
- Hosp Virgen de La Victoria - Málaga
New York
- Columbia University Medical Center Herbert Irving Pavilion - New York
- Memorial Sloan Kettering Cancer Center - New York
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2027-02-10 |
| Phase | Phase 1 |
What the registry record for NCT04898634 still lists
NCT04898634 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, below the 511-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-78278343 is the first listed.
NCT04898634 lists 17 locations in 3 states (Other, New York, Washington).
Frequently Asked Questions
What is clinical trial NCT04898634 about?
NCT04898634 is a clinical study titled "A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer". The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
What is the current status of trial NCT04898634?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2021-07-13. Estimated completion is 2027-02-10.
What conditions does trial NCT04898634 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT04898634?
The interventions under investigation include: JNJ-78278343 (DRUG).
Who is sponsoring clinical trial NCT04898634?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04898634 being conducted?
This trial has 17 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04898634's enrollment target sits among peer trials
216 31st of 65 higher than 35 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
RECRUITING · Phase 1
-
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
RECRUITING · Phase 1
-
A Study of DM002 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI